Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$4.08 USD
-0.11 (-2.51%)
Updated May 28, 2024 04:00 PM ET
After-Market: $4.08 +0.01 (0.12%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Rapt Therapeutics [RAPT]
Reports for Purchase
Showing records 61 - 74 ( 74 total )
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Next Week We''ll Kick Off Our Management Talk Series
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
GILD''s CCR8 Deal Highlights RAPT''s CCR4 Antagonist Potential in Oncology
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Awaiting FLX475 and RPT193 Data; 2Q20 Financials; Raising PT to $42
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
2Q20 Earnings - Two Major Catalysts Expected Before YE20. Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Dynamic Duo for Allergic Disorders and Cancer; Initiating at Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
We Expect Confirmatory PoC Data For RPT193 in Atopic Dermatitis by YE2020
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
1Q Update - Key Data Readouts Remain on Track for 2020
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Solid Long-Term Outlook With Strong Balance Sheet. Initiate Buy, $38 PT.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
We are sending out a reminder about our 33rd Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department